178 related articles for article (PubMed ID: 30619735)
1. The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients.
Taberna M; Torres M; Alejo M; Mena M; Tous S; Marquez S; Pavón MA; León X; García J; Guix M; Hijano R; Bonfill T; Aguilà A; Lozano A; Mesía R; Alemany L; Bravo IG
Front Oncol; 2018; 8():589. PubMed ID: 30619735
[No Abstract] [Full Text] [Related]
2. EGFR Protein Expression Relates with Tumor Histology, Methylation Status of EGFR and HPV16 E6 Viral Load in Oropharyngeal Carcinoma.
Suzuki Y; Fukumura Y; Asahina M; Fujimaki M; Ohba S; Matsumoto F; Kurahayashi I; Yao T; Ikeda K
Head Neck Pathol; 2021 Sep; 15(3):743-756. PubMed ID: 33428063
[TBL] [Abstract][Full Text] [Related]
3. Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer.
Um SH; Mundi N; Yoo J; Palma DA; Fung K; MacNeil D; Wehrli B; Mymryk JS; Barrett JW; Nichols AC
J Clin Virol; 2014 Sep; 61(1):94-100. PubMed ID: 25027574
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.
Rettig EM; Wentz A; Posner MR; Gross ND; Haddad RI; Gillison ML; Fakhry C; Quon H; Sikora AG; Stott WJ; Lorch JH; Gourin CG; Guo Y; Xiao W; Miles BA; Richmon JD; Andersen PE; Misiukiewicz KJ; Chung CH; Gerber JE; Rajan SD; D'Souza G
JAMA Oncol; 2015 Oct; 1(7):907-15. PubMed ID: 26226294
[TBL] [Abstract][Full Text] [Related]
6. Concordance of p16
Mena M; Wang X; Tous S; Quiros B; Clavero O; Alejo M; Morey F; Taberna M; Leon Vintro X; Lloveras Rubio B; Alos L; Mehanna H; Quint W; Pawlita M; Tommasino M; Pavón MA; Muñoz N; De Sanjose S; Bosch FX; Alemany L; On Behalf Of The Ico International Hpv In Head And Neck Cancer Study Group
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954451
[TBL] [Abstract][Full Text] [Related]
7. Double positivity for HPV-DNA/p16
Mena M; Taberna M; Tous S; Marquez S; Clavero O; Quiros B; Lloveras B; Alejo M; Leon X; Quer M; Bagué S; Mesia R; Nogués J; Gomà M; Aguila A; Bonfill T; Blazquez C; Guix M; Hijano R; Torres M; Holzinger D; Pawlita M; Pavon MA; Bravo IG; de Sanjosé S; Bosch FX; Alemany L
Oral Oncol; 2018 Mar; 78():137-144. PubMed ID: 29496041
[TBL] [Abstract][Full Text] [Related]
8. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
Anderson KS; Dahlstrom KR; Cheng JN; Alam R; Li G; Wei Q; Gross ND; Chowell D; Posner M; Sturgis EM
Oral Oncol; 2015 Jul; 51(7):662-7. PubMed ID: 25957822
[TBL] [Abstract][Full Text] [Related]
9. E1 detection as prognosticator in human papillomavirus-positive head and neck cancers.
Vivenza D; Lo Nigro C; Denaro N; Fortunato M; Monteverde M; Tonissi F; Lattanzio L; Astesana V; Gloghini A; Volpi CC; Russi E; Merlano MC
Int J Biol Markers; 2016; 31(2):0. PubMed ID: 27040135
[TBL] [Abstract][Full Text] [Related]
10. HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study.
Economopoulou P; Koutsodontis G; Avgeris M; Strati A; Kroupis C; Pateras I; Kirodimos E; Giotakis E; Kotsantis I; Maragoudakis P; Gorgoulis V; Scorilas A; Lianidou E; Psyrri A
PLoS One; 2019; 14(5):e0215984. PubMed ID: 31071126
[TBL] [Abstract][Full Text] [Related]
11. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
12. Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters.
Ramqvist T; Mints M; Tertipis N; Näsman A; Romanitan M; Dalianis T
Oral Oncol; 2015 Dec; 51(12):1126-31. PubMed ID: 26421862
[TBL] [Abstract][Full Text] [Related]
13. Characterization of human papillomavirus antibodies in individuals with head and neck cancer.
Lang Kuhs KA; Pawlita M; Gibson SP; Schmitt NC; Trivedi S; Argiris A; Kreimer AR; Ferris RL; Waterboer T
Cancer Epidemiol; 2016 Jun; 42():46-52. PubMed ID: 27010729
[TBL] [Abstract][Full Text] [Related]
14. The papillomavirus E5 gene does not affect EGFR transcription and overall survival in cervical cancer.
Basto DL; Chaves CBP; Felix SP; Amaro-Filho SM; Vieira VC; Martins LFL; de Carvalho NA; Almeida LM; Moreira MÂM
J Med Virol; 2020 Aug; 92(8):1283-1289. PubMed ID: 31696949
[TBL] [Abstract][Full Text] [Related]
15. Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology - A proof-of-concept study.
Busch CJ; Hoffmann AS; Viarisio D; Becker BT; Rieckmann T; Betz C; Bender N; Schroeder L; Hussein Y; Petersen E; Jagodzinski A; Schäfer I; Burandt E; Lang Kuhs K; Pawlita M; Waterboer T; Brenner N
EClinicalMedicine; 2022 Nov; 53():101659. PubMed ID: 36147627
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
[TBL] [Abstract][Full Text] [Related]
17. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes.
Varier I; Keeley BR; Krupar R; Patsias A; Dong J; Gupta N; Parasher AK; Genden EM; Miles BA; Teng M; Bakst RL; Gupta V; Misiukiewicz KJ; Chiao EY; Scheurer ME; Laban S; Zhang D; Ye F; Cui M; Demicco EG; Posner MR; Sikora AG
Head Neck; 2016 Sep; 38(9):1330-7. PubMed ID: 27080140
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.
Reimers N; Kasper HU; Weissenborn SJ; Stützer H; Preuss SF; Hoffmann TK; Speel EJ; Dienes HP; Pfister HJ; Guntinas-Lichius O; Klussmann JP
Int J Cancer; 2007 Apr; 120(8):1731-8. PubMed ID: 17236202
[TBL] [Abstract][Full Text] [Related]
20. Serum HPV16 E7 Oncoprotein Is a Recurrence Marker of Oropharyngeal Squamous Cell Carcinomas.
Oton-Gonzalez L; Rotondo JC; Lanzillotti C; Mazzoni E; Bononi I; Iaquinta MR; Cerritelli L; Malagutti N; Ciorba A; Bianchini C; Pelucchi S; Tognon M; Martini F
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
